Questions about treatment claims · 06
Which TB-500 claims can the evidence answer?
The copy mentioned in healing claims contains a section within a much larger protein. Twenty-five questions below cover what the studies measured and what remains uncertain. The answers also explain pharmacy rules that may affect your care.
What evidence concerns a damaged heart?
What survived heart damage in studies linked to TB-500?
Mice given thymosin beta-4 had better early heart-cell survival after a heart artery was closed by tying [2]. The larger protein also improved how those damaged hearts worked. Those thymosin beta-4 findings in mice don't show equal benefit from the small copy in your heart.
Do TB-500 heart studies establish help after a patient's heart attack?
An animal study reported less heart damage with thymosin beta-4 circulating through the body after blood supply was lost [8]. Mice in another study had fewer heart-wall tears [10]. The finished human trial used thymosin beta-4 [12], while pigs received repair cells changed to supply the protein [13]. These results haven't shown protection from the small copy for your heart.
What does the finished thymosin beta-4 heart trial tell patients?
The human heart-attack trial of thymosin beta-4 is marked as finished, without patient results reported in the public listing [12]. Published findings haven't shown human benefit from TB-500 [12]. The trial's ending doesn't tell how well the patients recovered.
How can I tell which substance a claim concerns?
Why is TB-500 called a small copy?
TB-500 copies a section of thymosin beta-4, a 43-amino-acid protein, meaning a chain of joined protein parts [1]. Most healing studies tested the whole protein, whose results do not automatically apply to the copy. Researchers and animal-care workers use the substance, without approval for treating your illness [12].
How did TB-500 get its name?
The letters in TB-500 come from thymosin beta, referring to the fragment copied from thymosin beta-4 [5]. Animal-care workers use the same name, without settling your human treatment question. Most healing findings used the whole protein, so a name alone doesn't identify what produced a study result.
What injuries interest researchers studying TB-500?
Studies examine thymosin beta-4 and the section that holds actin, a protein used when cells move, in animals and dishes [5]. Injuries include skin and eye wounds, damaged muscles and ligaments, and heart or brain damage. Researchers also examine hair growth and the formation of blood vessels, without establishing approved treatment for you.
Why do researchers look at movement inside cells?
What connects cell movement with TB-500 research?
TB-500 copies the section of thymosin beta-4 that holds actin, a protein used to form strands inside moving cells [1]. The larger protein keeps some actin ready so cells can change shape and move toward injuries. Injury studies found more vessels forming, fewer scars, and less swelling and soreness with the whole protein [5]. Human studies haven't shown equal changes from the small copy.
Could blood-vessel growth linked to TB-500 also harm someone?
Thymosin beta-4 helped cells lining blood vessels move and form vessels in dish and animal studies [5]. Blood reaching damaged tissue can help repair a wound. A tumor could use the same new blood supply to grow, which raises a safety concern.
Do TB-500 cell tests prove relief from swelling?
Heat, swelling, or soreness after injury or illness can come from a response called inflammation. In laboratory dishes containing cells, thymosin beta-4 reduced release of a substance that drives that response [9]. Animal studies also found less liver scarring and less of that response with the larger protein. Those experiments haven't shown symptom relief from the copy for you.
What limits apply to animal healing findings?
Did muscle studies linked to TB-500 show greater strength?
Thymosin beta-4 attracted developing muscle cells toward injury and helped injured rat ligaments heal [5]. Lengthy thymosin beta-4 treatment increased the regrowth of muscle fibers in mice with muscle disease [5]. The mice gained no strength from the extra fibers, so more regrowth didn't mean stronger muscles.
What can TB-500 ligament research tell me about a tendon injury?
Thymosin beta-4 improved healing of injured inner-knee ligaments in rats [5]. Ligaments hold bones together; tendons connect muscles with bones. The larger-protein rat result doesn't show that the copy heals either structure in your body.
Which TB-500 wound findings used a shorter protein chain?
Animals' skin and eye wounds healed faster with thymosin beta-4, while collagen, a protein that makes tissue strong, increased. Rats formed up to 61% more new skin than comparison rats at 7 days, rather than that share of a wound closing [3]. Researchers also made a shorter chain containing the actin-holding section, which repeated some of the wound-healing activity [5]. The shorter-chain experiment gives a reason to study repair, without proving treatment helps your wound.
Can TB-500 animal results set a waiting time for my recovery?
No human study has established when a benefit would appear. Rats given thymosin beta-4 formed 42% more new skin than salt-water-treated rats at 4 days and up to 61% more at 7 days [3]. Those figures compare skin growth, not wound closure, and cannot predict your healing time.
Which ability improved after stroke in studies linked to TB-500?
Amounts were based on kilograms of body weight, each just over two pounds. Thymosin beta-4 improved rats' control of movement at 2 or 12 milligrams per kilogram; the 18 milligrams per kilogram amount did not help [4]. Injections went into the space around belly organs, and the rat study cannot show a treatment amount for people after stroke.
What do TB-500 hair studies establish about hair loss?
Thymosin beta-4 stirred cells around hair roots into activity, and mice and rats grew hair faster [5]. The larger protein was tested at tiny amounts in those experiments. The animal changes don't show hair-loss treatment with the copy for you.
What has testing established about safety in people?
What is known about my chance of TB-500 side effects?
No finished study in people compares the copy's safety with other care [12]. Volunteers tolerated whole thymosin beta-4 up to 1260 milligrams during Phase 1, an early vein-injection safety study [6]. Possible blood vessels helping tumors grow remain a concern [5], while research-product contents may also be uncertain.
Has a human study shown cancer harm from TB-500?
Laboratory tests found unusually large amounts of thymosin beta-4 in several cancers, linked to spread and blood vessels supplying tumors [5]. The same actions could help repair tissue or help cancer. A finished human safety trial hasn't settled that possible harm from the copy for your care [12].
What evidence covers years of TB-500 use?
TB-500 lacks controlled human evidence establishing safety over long use [12]. Possible tumor growth [5] and uncertain ingredients in research products remain concerns. People describe larger starting amounts followed by smaller amounts, but controlled trials haven't checked those plans [12].
Did any finished human trial test TB-500 itself?
No human trial comparing TB-500 with other care has finished [12]. Whole thymosin beta-4 underwent a Phase 1 safety study using injections into a vein [6]. Chance determined who received the protein or a placebo, a preparation without the tested substance. The larger protein was used in eye trials and in a finished heart-attack trial; an earlier heart trial enrolled nobody [12].
Does the research identify a better treatment between TB-500 and BPC-157?
Both unapproved substances appeared in a 2026 review of research about muscle, bone, and joint repair [7]. Most healing findings linked to TB-500 used whole thymosin beta-4 [5]. Neither substance has FDA drug approval, and the review doesn't show which would help your injury [12].
How do approval, prescriptions, and sports rules differ?
When does the TB-500 sports ban apply?
Sports governed by the World Anti-Doping Agency's rules prohibit TB-500 and thymosin beta-4 [12]. The rules cover both competing and the time between events. Human samples and samples taken from horses can reveal use during testing.
Has TB-500 received approval to treat illness?
FDA hasn't approved TB-500 treatment for illness, although researchers and animal-care workers use the substance [12]. FDA placed the thymosin beta-4 fragment called TB-500 in Category 2, a group for pharmacy ingredients raising serious safety concerns [14]. Section 503A governs medicine prepared to meet an individual patient's needs, separate from drug approval.
Does a withdrawn pharmacy request establish lawful TB-500 treatment?
FDA has granted no drug approval for TB-500; sports rules prohibit use, and some countries apply prescription-medicine rules [12]. FDA placed the ingredient in section 503A's Category 2 safety-risk group on September 29, 2023 [14]. FDA's page dated April 22, 2026 shows TB-500 outside Category 2 after the group seeking pharmacy permission withdrew its request. FDA gives no withdrawal date and leaves pharmacy permission unanswered following withdrawal.
What would a prescriber need before arranging TB-500 pharmacy care?
A licensed prescriber must assess your health and write an appropriate prescription [16]. Section 503A pharmacies prepare individual medicines; section 503B facilities make larger batches, and both need lawful ingredients. FDA hasn't clearly answered whether a 503A pharmacy may use TB-500 after withdrawal, and the safety concerns remain [14][16]. No particular pharmacy or prescriber is identified here to settle your case.
Did advisers clear either TB-500 form for section 503A preparation?
FDA placed the thymosin beta-4 fragment TB-500 in 503A Category 2 on September 29, 2023 because of safety concerns [14]. The pharmacy request was withdrawn, leaving TB-500 outside Category 2 without a clear answer about permitted preparation. The July 23-24, 2026 meeting considered two forms for the 503A list: free base without a paired acid, and acetate paired with part of an acid found in vinegar. That pairing is a chemical salt, distinct from table salt; FDA staff opposed both forms and hadn't published votes by September 2026 [14].